サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1439242

ニューロモデュレーションデバイス - 世界市場の考察、競合情勢、市場予測（2030年）

Neuromodulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ニューロモデュレーションデバイス - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のニューロモデュレーションデバイスの市場規模は、2023年に57億1,000万米ドル、2030年までに95億6,000万米ドルに達し、2024年～2030年の予測期間にCAGRで8.95％の成長が見込まれます。ニューロモデュレーションデバイスの需要は主に、老年人口の増加と神経疾患の有病率の増加、その他の慢性適応症や対象用途へのデバイスの拡張、製品ポートフォリオにおける技術の進歩、神経疾患に関する患者の意識を高める政府の取り組みの高まりなどによって促進されています。

ニューロモデュレーションデバイスの市場力学

神経疾患とは、主に脳、脊髄、脳神経、末梢神経、神経根、自律神経系、神経筋接合部、筋肉を含む中枢神経系と末梢神経系に影響を及ぼす疾患です。世界保健機関（WHO）が2023年に提供したデータによると、全世界で約5,000万人がてんかんを患っており、2019年に世界的にもっとも一般的な神経疾患の1つとなっています。てんかん患者の約80％は低中所得国に住んでいます。

WHOが2023年に発表したデータによると、約5,500万人が認知症を患っており、毎年1,000万人近くが新たに発症しています。

ニューロモデュレーションとは、神経に直接作用する技術です。標的部位に直接電気刺激を与えることで、神経活動を変化させます（あるいは調節します）。ニューロモデュレーションデバイスは、てんかん、片頭痛、パーキンソン病などのさまざまな神経疾患の治療や症状の軽減を目的として、脳、脊髄、末梢神経に電極を装着します。したがって、世界中でのさまざまな神経疾患の有病率の増加は、世界のニューロモデュレーションデバイス市場の成長促進要因となる可能性があります。

さらに、ニューロモデュレーションデバイスは、頭痛から振戦、脊髄損傷、尿失禁など、ほとんどすべての疾患や症状を治療します。このように治療範囲が広く、バイオテクノロジーが継続的に大きく改良されていることから、ニューロモデュレーションが予測期間に高成長産業として位置づけられるのも当然です。慢性疼痛の治療に加え、パーキンソン病に対する脳深部刺激（DBS）療法、骨盤疾患に対する仙骨神経刺激、尿失禁など、ニューロモデュレーションの応用例は多いです。例えば、MedtronicのENTERRA II NEUROSTIMULATORは胃神経刺激デバイスであり、胃の電気刺激に用いる微弱な電気パルスを発生させ、胃不全麻痺による慢性的な難治性の吐き気や嘔吐を治療します。

したがって、その他の慢性的な適応症や標的用途へのデバイスの使用の拡大も、世界のニューロモデュレーションデバイス市場を促進すると予測されます。

しかし、これらのデバイスの高いコストや診断率および治療率の低下といった特定の要因が、ニューロモデュレーションデバイス市場の成長を抑制する可能性が高いです。

ニューロモデュレーションデバイス市場のセグメント分析

ニューロモデュレーションデバイス製品セグメントでは、脊髄刺激デバイスが予測期間に大きな市場を占めます。これは、慢性疼痛、脊椎手術後痛症候群、複合性局所疼痛症候群（CRPS）の患者人口が増加しているためです。例えば、CDC（2020）のデータによると、2019年に成人の20.4%が慢性疼痛を有し、成人の7.4%が生活や仕事の活動を頻繁に制限する慢性疼痛（高負荷慢性疼痛と呼ばれる）を有し、どちらも年齢とともに増加し、65歳以上の成人でもっとも高くなっています。

さらに、充電式バッテリーや無線遠隔技術を搭載した先進技術を利用した脊髄刺激デバイスの近年の製品の発売も、このセグメントの成長に寄与しています。例えば、2020年にBoston Scientific Corporationが欧州で脊髄刺激デバイス（SCS）システムのWaveWriter Alpha（TM）ポートフォリオを発売しました。同ポートフォリオは、4種類のMRI条件付きBluetooth対応植込み型パルスジェネレーター（IPG）で構成されており、充電式と非充電式のオプションや、複数の疼痛領域をカバーできる波形へのアクセスなど、患者のニーズに基づいたパーソナライゼーションの幅を広げています。

当レポートでは、世界のニューロモデュレーションデバイス市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 ニューロモデュレーションデバイスレポートのイントロダクション

第2章 ニューロモデュレーションデバイスのエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 ニューロモデュレーションデバイス市場の主な要因の分析

  • ニューロモデュレーションデバイス市場の促進要因
    • 老年人口の増加と神経疾患の有病率の増加
    • その他の慢性疾患と対象用途へのデバイスの拡張
    • 製品ポートフォリオにおける技術の進歩
    • 神経疾患に対する患者の意識を高める政府の取り組みの高まり
  • ニューロモデュレーションデバイス市場の抑制要因と課題
    • デバイスと処置の高いコスト
    • 複雑な規制当局の承認シナリオ
  • ニューロモデュレーションデバイス市場の機会
    • 非侵襲性のデバイスに対する需要の高まり
    • 発展途上国における市場成長機会

第5章 ニューロモデュレーションデバイスのポーターのファイブフォース分析

第6章 ニューロモデュレーションデバイス市場のレイアウト

  • タイプ別
    • 侵襲性
    • 非侵襲性
  • 製品タイプ別
    • 脊髄刺激デバイス
    • 迷走神経刺激デバイス
    • 脳深部刺激デバイス
    • 仙骨神経刺激デバイス
    • 経頭蓋磁気刺激デバイス
    • その他
  • 用途別
    • 疼痛管理
    • 神経障害
    • 呼吸器障害
  • エンドユーザー別
    • 病院
    • 専門クリニック
  • 地域別
    • 北米
    • 欧州のニューロモデュレーションデバイスの市場規模（2021年～2030年）
    • アジア太平洋のニューロモデュレーションデバイスの市場規模（2021年～2030年）
    • その他の地域のニューロモデュレーションデバイスの市場規模（2021年～2030年）

第7章 ニューロモデュレーションデバイスの企業と製品のプロファイル

  • Medtronic
  • Boston Scientific Corporation
  • Abbott
  • LivaNova
  • NeuroSigma
  • NEVRO CORP.
  • Synapse Biomedical Inc.
  • NeuroPace, Inc.
  • Bioventus
  • Soterix Medical Inc.
  • Helius Medical Technologies
  • Axonics, Inc.
  • MicroTransponder Inc.
  • electroCore, Inc.

第8章 KOLの見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightのサービス内容

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Neuromodulation Devices Market in Global (2021-2030)
  • Table 3: Neuromodulation Devices Market in Global by Type (2021-2030)
  • Table 4: Neuromodulation Devices Market in Global by Product (2021-2030)
  • Table 5: Neuromodulation Devices Market in Global by Application (2021-2030)
  • Table 6: Neuromodulation Devices Market in Global by End-User (2021-2030)
  • Table 7: Neuromodulation Devices Market in Global by Geography (2021-2030)
  • Table 8: Neuromodulation Devices Market in North America (2021-2030)
  • Table 9: Neuromodulation Devices Market in the US (2021-2030)
  • Table 10: Neuromodulation Devices Market in Canada (2021-2030)
  • Table 11: Neuromodulation Devices Market in Mexico (2021-2030)
  • Table 12: Neuromodulation Devices Market in Europe (2021-2030)
  • Table 13: Neuromodulation Devices Market in France (2021-2030)
  • Table 14: Neuromodulation Devices Market in Germany (2021-2030)
  • Table 15: Neuromodulation Devices Market in the United Kingdom (2021-2030)
  • Table 16: Neuromodulation Devices Market in Italy (2021-2030)
  • Table 17: Neuromodulation Devices Market in Spain (2021-2030)
  • Table 18: Neuromodulation Devices Market in Rest of Europe (2021-2030)
  • Table 19: Neuromodulation Devices Market in Asia-Pacific (2021-2030)
  • Table 20: Neuromodulation Devices Market in China (2021-2030)
  • Table 21: Neuromodulation Devices Market in Japan (2021-2030)
  • Table 22: Neuromodulation Devices Market in India (2021-2030)
  • Table 23: Neuromodulation Devices Market in Australia (2021-2030)
  • Table 24: Neuromodulation Devices Market in South Korea (2021-2030)
  • Table 25: Neuromodulation Devices Market in Rest of Asia-Pacific (2021-2030)
  • Table 26: Neuromodulation Devices Market in the Rest of the World (2021-2030)
  • Table 27: Neuromodulation Devices Market in the Middle East (2021-2030)
  • Table 28: Neuromodulation Devices Market in Africa (2021-2030)
  • Table 29: Neuromodulation Devices Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Neuromodulation Devices Market in Global (2021-2030)
  • Figure 3: Neuromodulation Devices Market in Global by Type (2021-2030)
  • Figure 4: Neuromodulation Devices Market in Global by Product (2021-2030)
  • Figure 5: Neuromodulation Devices Market in Global by Application (2021-2030)
  • Figure 6: Neuromodulation Devices Market in Global by End-User (2021-2030)
  • Figure 7: Neuromodulation Devices Market in Global by Geography (2021-2030)
  • Figure 8: Neuromodulation Devices Market in North America (2021-2030)
  • Figure 9: Neuromodulation Devices Market in the US (2021-2030)
  • Figure 10: Neuromodulation Devices Market in Canada (2021-2030)
  • Figure 11: Neuromodulation Devices Market in Mexico (2021-2030)
  • Figure 12: Neuromodulation Devices Market in Europe (2021-2030)
  • Figure 13: Neuromodulation Devices Market in France (2021-2030)
  • Figure 14: Neuromodulation Devices Market in Germany (2021-2030)
  • Figure 15: Neuromodulation Devices Market in the United Kingdom (2021-2030)
  • Figure 16: Neuromodulation Devices Market in Italy (2021-2030)
  • Figure 17: Neuromodulation Devices Market in Spain (2021-2030)
  • Figure 18: Neuromodulation Devices Market in Rest of Europe (2021-2030)
  • Figure 19: Neuromodulation Devices Market in Asia-Pacific (2021-2030)
  • Figure 20: Neuromodulation Devices Market in China (2021-2030)
  • Figure 21: Neuromodulation Devices Market in Japan (2021-2030)
  • Figure 22: Neuromodulation Devices Market in India (2021-2030)
  • Figure 23: Neuromodulation Devices Market in Australia (2021-2030)
  • Figure 24: Neuromodulation Devices Market in South Korea (2021-2030)
  • Figure 25: Neuromodulation Devices Market in Rest of Asia-Pacific (2021-2030)
  • Figure 26: Neuromodulation Devices Market in the Rest of the World (2021-2030)
  • Figure 27: Neuromodulation Devices Market in the Middle East (2021-2030)
  • Figure 28: Neuromodulation Devices Market in Africa (2021-2030)
  • Figure 29: Neuromodulation Devices Market in South America (2021-2030)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Market Opportunities
  • Figure 33: PORTER's Five Force Analysis
目次
Product Code: DIMDCL0029

Neuromodulation Devices Market By Type (Invasive and Non-Invasive), Product (Spinal Cord Stimulators, Vagus Nerve Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Transcranial Magnetic Stimulators, and Others), Application (Pain Management, Neurological Disorder, Respiratory Disorders, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography is expected to grow at a static CAGR forecast till 2030 due to Advances in Product Portfolio and Burgeoning Neurological Disorder Prevalence among the aging population

The global neuromodulation devices market was valued at USD 5.71 billion in 2023, growing at a CAGR of 8.95% during the forecast period from 2024 to 2030, to reach USD 9.56 billion by 2030. The demand for neuromodulation devices is primarily motivated by the increasing prevalence of neurological disorders coupled with the rising aging population, expansion of the devices to other chronic indications and target applications, technological advancement in the product portfolio, rising government initiatives to raise awareness among patient regarding neurological disorders, among others.

Neuromodulation Devices Market Dynamics:

Neurological disorders are diseases that affect the central and peripheral nervous system which primarily include the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscles. According to the data provided by the World Health Organization (WHO) 2023, approximately 50 million people across the globe were suffering from epilepsy, making it one of the most common neurological diseases globally in 2019. About 80% of people with epilepsy live in low- and middle-income countries.

As per the data provided by WHO 2023, about 55 million people are living with dementia, and there are nearly 10 million new cases every year.

Neuromodulation is a technique that directly acts on nerves. It changes (or modulates) nerve activity by delivering electrical stimulation directly to the target area. Neuromodulation devices involve applying electrodes to the brain, spinal cord, or peripheral nerves to treat or reduce the symptom of various neurological disorders such as epilepsy, migraine, and Parkinson's disease, among others. Therefore the rising prevalence of various neurological disorders across the globe could be a potential factor leading to the growth of the global neuromodulation devices market.

Moreover, neuromodulation devices treat almost all diseases or symptoms, from headaches to tremors, spinal cord injuries and urinary incontinence, and others. With such a wide range of treatments and significant continuous improvements in biotechnology, it is not surprising that neuromodulation is positioned as a high-growth industry during the forecasted period. In addition to treating chronic pain, there are many neuromodulation applications, such as deep brain stimulation (DBS) treatment for Parkinson's disease, sacral nerve stimulation for pelvic diseases, and urinary incontinence. For instance, ENTERRA II NEUROSTIMULATOR by Medtronic is a gastric neurostimulator that generates mild electrical pulses for gastric electrical stimulation to treat chronic, intractable nausea and vomiting due to gastroparesis.

Therefore, the expansion of device usage to other chronic indications and targeted applications is also anticipated to propel the global neuromodulation devices market.

However, certain factors such as the high cost of these devices and the lower rate of diagnosis and treatment are likely to impede the growth of the neuromodulation devices market.

Neuromodulation Devices Market Segment Analysis:

Neuromodulation Devices Market by Type (Invasive and Non-Invasive), Product (Spinal Cord Stimulators, Vagus Nerve Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Transcranial Magnetic Stimulators, and Others), Application (Pain Management, Neurological Disorder, Respiratory Disorders, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the neuromodulation devices product segment, spinal cord stimulators hold a significant market during the forecasted period. This is owing to the growing patient population suffering from chronic pain, failed back syndrome, and complex regional pain syndrome (CRPS). For instance, according to CDC 2020 data, in 2019, 20.4% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities (referred to as high-impact chronic pain) and both increased with age and were highest among adults aged 65 and over.

Moreover, recent product launches of technologically advanced spinal cord stimulators with rechargeable batteries and wireless remote techniques also contribute to segmental growth. For instance, in 2020, Boston Scientific Corporation launched the WaveWriter Alpha(TM) portfolio of Spinal Cord Stimulator (SCS) Systems in Europe. The portfolio consists of four MRI conditional, Bluetooth-enabled implantable pulse generators (IPGs), that offer expanded personalization based on patient needs, including rechargeable and non-rechargeable options, and access to waveforms that can cover multiple areas of pain.

In addition, emerging guidelines from the government for spinal cord stimulation therapy for the treatment of chronic pain and other indications are also anticipated to augment the market. For instance, in January 2019, National Institute for Health and Care Excellence (NICE) published guidelines and recommendations for Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.

Hence, all the mentioned factors are likely to fuel the segmental growth of the Neuromodulation Devices market during the forecasted period.

North America is expected to dominate the overall Neuromodulation Devices Market:

North America is expected to dominate the overall Neuromodulation Devices market during the forecast period. This domination is due to the increased healthcare expenditure along with the presence of a well-developed and advanced healthcare system in the region. Moreover, higher diagnosis and treatment rates and adequate reimbursement policies are the driving factors.

Further, In the United States, the presence of neuromodulation device companies in the market such as Abbott, Boston Scientific Corporation, and Medtronic, among others is likely to boost the market. Also, the growing prevalence of neurological disorders such as Parkinson's disease, epilepsy, migraine, and treatment-resistant depressive order is expected to bolster the market. For instance, as per the Parkinson's Foundation 2022 study, every year in the United States about 90,000 people are diagnosed with Parkinson's disease. Thus, rising cases of Parkinson's among other neurological disorders could be a significant factor for the neuromodulation devices market growth.

Moreover, an increase in product approval by FDA is also a driving factor for neuromodulation devices in the region. For instance, in June 2020, Medtronic received Food and Drug Administration (FDA) approval for the Percept(TM) PC Deep Brain Stimulation (DBS) system. BrainSense(TM) technology makes Percept the first and only DBS neurostimulation system with the ability to chronically capture and record brain signals while delivering therapy to patients with neurologic disorders associated with Parkinson's disease, essential tremor, dystonia, epilepsy, or obsessive-compulsive disorder (OCD).

Thus, the aforementioned factors are likely to upsurge the market for neuromodulation devices in the region.

Neuromodulation Devices Market Key Players:

Some of the key market players operating in the neuromodulation devices market include Medtronic,

Boston Scientific Corporation, Abbott, LivaNova, NeuroSigma, NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus., Soterix Medical Inc., and others.

Recent Developmental Activities in Neuromodulation Devices Market:

In March 2021, Axonics Modulation Technologies, Inc. entered into a strategic alliance with Micro Systems Technologies (MST) for the manufacture of a non-rechargeable implantable sacral neuromodulation device.

In March 2021, Helius Medical received the US FDA approval for Portable Neuromodulation Stimulator approval for short-term treatment of gait deficit due to multiple sclerosis.

In January 2021, Boston Scientific Corporation received FDA approval for its fourth-generation Vercise Genus Deep Brain Stimulation (DBS) System used to treat symptoms in patients with advanced Parkinson's disease.

Key Takes Away from the Neuromodulation Devices Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global neuromodulation devices market.

Various opportunities available for the other competitor in the neuromodulation devices market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for neuromodulation devices market growth in the coming future?

Target Audience who can be benefited from Neuromodulation Devices Market Report Study

Neuromodulation Devices providers

Research organizations and consulting companies

Neuromodulation Devices-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders in Neuromodulation Devices

Various End-Users who want to know more about the neuromodulation devices market and the latest technological developments in the neuromodulation devices market.

Frequently Asked Questions for Neuromodulation Devices Market:

1. What are neuromodulation devices?

Neuromodulation devices, also known as neurostimulation devices involve the application of electrodes to the brain, the spinal cord, or peripheral nerves. These devices can increase or decrease the activity of the nervous system by generating necessary electrical stimulation.

2. What is the market for global neuromodulation devices?

The global neuromodulation devices market was valued at USD 5.71 billion in 2023, growing at a CAGR of 8.95% during the forecast period from 2024 to 2030, to reach USD 9.56 billion by 2030.

3. What are the drivers for global neuromodulation devices?

The major factors driving the demand for neuromodulation devices are the growing prevalence of neurological disorders coupled with the rising geriatric population, expanding device application in various other indications, and the launch of technically advanced products in the market.

4. What are the key players operating in global neuromodulation devices?

Some of the key market players operating in the neuromodulation devices market include Medtronic, Boston Scientific Corporation, Abbott, LivaNova, NeuroSigma, NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus., Soterix Medical Inc., and others

5. Which region has the highest share in the neuromodulation devices market?

North America is anticipated to dominate the overall Neuromodulation Devices market during the forecast period, 2024-2030 due to the increased healthcare expenditure along with the presence of a well-developed and advanced healthcare system in the region. Furthermore, rising diagnosis and treatment rates and adequate reimbursement policies also contribute to the highest regional share.

Table of Contents

1. Neuromodulation Devices Report Introduction

2. Neuromodulation Devices Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Neuromodulation Devices Market Key Factors Analysis

  • 4.1. Neuromodulation Devices Market Drivers
    • 4.1.1. Increasing prevalence of neurological disorder coupled with a rising aging population
    • 4.1.2. Expansion of the devices to other chronic indications and target application
    • 4.1.3. Technological advancement in the product portfolio
    • 4.1.4. Rising government initiative to raise awareness among patients regarding neurological disorders
  • 4.2. Neuromodulation Devices Market Restraints and Challenges
    • 4.2.1. High cost of the devices and procedure
    • 4.2.2. Complex regulatory approval scenario
  • 4.3. Neuromodulation Devices Market Opportunities
    • 4.3.1. Growing demand for non-invasive devices
    • 4.3.2. Market growth opportunities in developing nations

5. Neuromodulation Devices Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. Neuromodulation Devices Market layout

  • 6.1. By Type
    • 6.1.1. Invasive
    • 6.1.2. Non-invasive
  • 6.2. By Product Type
    • 6.2.1. Spinal Cord Stimulators
    • 6.2.2. Vagus Nerve Stimulators
    • 6.2.3. Deep Brain Stimulators
    • 6.2.4. Sacral Nerve Stimulators
    • 6.2.5. Transcranial Magnetic Stimulators
    • 6.2.6. Others
  • 6.3. By Application
    • 6.3.1. Pain Management
    • 6.3.2. Neurological disorder
    • 6.3.3. Respiratory disorder
    • 6.3.4. Others
  • 6.4. By End-User
    • 6.4.1. Hospitals
    • 6.4.2. Specialty Clinics
    • 6.4.3. Others
  • 6.5. By Geography
    • 6.5.1. North America
      • 6.5.1.1. United States Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.1.2. Canada Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.1.3. Mexico Neuromodulation Devices Market Size in USD million (2021-2030)
    • 6.5.2. Europe Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.2.1. France Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.2.2. Germany Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.2.3. United Kingdom Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.2.4. Italy Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.2.5. Spain Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.2.6. Rest of Europe Neuromodulation Devices Market Size in USD million (2021-2030)
    • 6.5.3. Asia-Pacific Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.3.1. China Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.3.2. Japan Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.3.3. India Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.3.4. Australia Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.3.5. South Korea Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.3.6. Rest of Asia-Pacific Neuromodulation Devices Market Size in USD million (2021-2030)
    • 6.5.4. Rest of the World (RoW) Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.4.1. Middle East Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.4.2. Africa Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.4.3. South America Neuromodulation Devices Market Size in USD million (2021-2030)

7. Neuromodulation Devices Company and Product Profiles

  • 7.1. Medtronic
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. Boston Scientific Corporation
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. Abbott
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. LivaNova
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. NeuroSigma
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. NEVRO CORP.
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. Synapse Biomedical Inc.
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. NeuroPace, Inc.
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. Bioventus
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. Soterix Medical Inc.
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4. Product Listing
    • 7.10.5. Entropy
  • 7.11. Helius Medical Technologies
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. Axonics, Inc.
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy
  • 7.13. MicroTransponder Inc.
    • 7.13.1. Company Overview
    • 7.13.2. Company Snapshot
    • 7.13.3. Financial Overview
    • 7.13.4. Product Listing
    • 7.13.5. Entropy
  • 7.14. electroCore, Inc.
    • 7.14.1. Company Overview
    • 7.14.2. Company Snapshot
    • 7.14.3. Financial Overview
    • 7.14.4. Product Listing
    • 7.14.5. Entropy

8. KOL Views

9. Project Approach

10. DelveInsight Capabilities

11. About DelveInsight

12. Disclaimer & Contact Us